The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...

Halozyme Therapeutics is entering a powerful earnings inflection. FY25 revenue grew 38% to $1.397 billion. Check out why I am bullish on HALO stock.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.

The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.

A WVU Cancer Institute team has achieved a global medical first in a clinical trial examining the efficacy of subcutaneous blinatumomab in treating one of the rarest ...

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...

The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.

Halozyme Therapeutics has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio and its subcutaneous injection platform. The ...

Dr. Dan Thomson shares essential tips for injections, needle selection and syringe maintenance to ensure herd health and ...

Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment -- VK2735 Maintenance Dosing Study Fully Enrolled; Data Expected ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...